Stuart Kurlander is highly regarded for his expert reimbursement practice and is well-versed in dealing with federal agencies and representing clients in front of the Centers for Medicare and Medicaid Services. Clients say he is “fluent in the industry” he has a “keen understanding of the complex regulatory landscape” and is a “thought leader in policy issues.”Chambers USA 2015-2017

Stuart S. Kurlander

Washington, D.C.
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA
 
 

Stuart Kurlander, a healthcare and life sciences partner in Latham & Watkins’ Washington, D.C. office, is global Co-chair of the Israel Practice and former global Co-chair of the Healthcare & Life Sciences Practice. Mr. Kurlander has more than 25 years of experience providing healthcare regulatory, reimbursement, fraud and abuse, corporate and litigation counsel to healthcare and life science companies including medical device and diagnostic manufacturers, pharmaceutical and biotech firms, and many other sectors of the industry.

Mr. Kurlander represents healthcare interests at all levels of government involving in matters before the Centers for Medicare and Medicaid Services (CMS), Office of the Inspector General (OIG), and the Public Health Service (PHS). He serves as outside regulatory counsel to several private equity funds, investment banks and venture capital funds where he routinely advises on transactions. Additionally, Mr. Kurlander:

  • Counsels companies on Medicare and Medicaid coverage, coding and reimbursement matters
  • Advises companies on federal and state fraud and abuse matters including development of compliance programs
  • Represents healthcare and life science companies on regulatory issues related to mergers and acquisitions, IPOs, financings and joint ventures in the US and also advises on transactions in the Middle East, Europe and Asia
  • Provides healthcare and life sciences counsel in complex litigation matters, including qui tam (whistleblowers lawsuits), and regularly negotiates with the US Department of Justice (DOJ), the US Department of Health and Human Services Office (HHS) of Inspector General and the Center for Medicare and Medicaid Services (CMS)

Mr. Kurlander previously served as an attorney in the General Counsel’s office of the US HHS, CMS where he drafted Medicare and Medicaid regulations, and litigated complex Medicare and Medicaid cases in federal court.

Mr. Kurlander has been recognized for several years as a leading healthcare and life sciences lawyer by Chambers USA and The Legal 500 US for his healthcare practice. He was named a regulatory “Life Sciences Star” by LMG Euromoney and as one of the Top 10 outstanding hospital and nursing home lawyers by Nightingale’s Healthcare News.

Additionally, he regularly authors legal and regulatory articles and columns in major healthcare publications, speaks nationally on emerging topics and trends, and is active in national and international healthcare, legal, civic and community organizations.

Mr. Kurlander has represented a number of clients in the health care and life sciences industry, including:

  • AdvaMed

  • Allergan
  • Alliqua BioMedical
  • Breg
  • Eagle Pharmaceuticals   
  • Edwards Life Sciences
  • Integra LifeSciences
  • Mapp Biopharmaceutical
  • US Renal Care

In the past five years, Mr. Kurlander has advised on the following matters:

Regulatory/Reimbursement

  • Reimbursement counselling and strategy for Eagle Pharmaceuticals, Inc. a specialty pharmaceutical company
  • Medicare coverage advocacy for Coalition of Manufacturers of Speech Generating Devices (SGD)
  • Reimbursement counselling for Zogenix, a pharmaceutical company Licensing, government contracts
  • Regulatory counselling for Mapp Biopharmaceutical, pharmaceutical company
  • Reimbursement counselling for Nxthera, an emerging medical device company

Capital Markets

  • Underwriters in Inovalon’s US$684 million IPO.
  • Underwriters in Surgery Partners, Inc.’s US$301 million IPO.
  • Underwriters in American Renal Associates Holdings, Inc.’s US$189 million IPO.
  • Teladoc in its US$180 million IPO.
  • Underwriters in Tornier N.V.’s US$166 million IPO.
  • Underwriters in Globus Medical Inc’s US$115 million IPO.

Mergers & Acquisitions

  • Sale by Allergan of its Global Generic Pharmaceuticals Business to Teva Pharmaceutical for US$40.5 billion.
  • Sale of Questcor Pharmaceuticals, a biopharmaceutical company, to Mallinckrodt for US$5.6 billion.
  • Acquisition by Leonard Green & Partners of ExamWorks Group, a provider of independent medical examinations (IMEs), peer and bill reviews, and related health care services for US$2.2 billion.
  • Acquisition by Cerner Corporation of the Health Information Technology Business Unit of Siemens, a provider of administrative hospital IT and electronic patient records for US$1.3 billion.
  • Sale of Ellipse Technologies, a developer of minimally invasive treatments for spinal deformities, to NuVasive.
  • Merger of equals between Sirona Dental Systems and DENTSPLY International to create a manufacturer of professional dental products and technologies.
  • Acquisition by U.S. Renal Care of DSI Renal, a provider of dialysis for patients suffering with chronic kidney failure and renal disease.
  • Sale of AqueSys, an ophthalmic company focused on implantable devices for the treatment of glaucoma, to Allergan.
  • Majority investment by Cinven in Medpace, a leading contract research organization.
  • Acquisition and then sale by Nestlé Health Science of Pamlab, L.L.C., a developer and manufacturer of prescription medical foods.
  • Acquisition by One Call Medical, a portfolio company of Odyssey Investment Partners, of TechHealth, a provider of cost containment services for workers’ compensation insurance claims.
  • Acquisition by One Call Medical of MSC Care Management, a care management company serving post-discharge and post-injury workers’ compensation patients.
  • Acquisition by Walgreen Co. of Crescent Healthcare, Inc. a California-based infusion pharmacy provider.
  • Acquisition by Thoratec Corporation of the medical business of Levitronix LLC, a company engaged in the development and production of medical blood pumps and fluid handling devices.
  • Acquisition by Integra LifeSciences Holdings Corporation of SeaSpine, Inc., a spine fusion medical device company.
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.